Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Straker, D. Articles by Manu, P. Search for Related Content PubMed Citation Articles by Straker, D. Articles by Manu, P. Neuroendocrinology Atypical Neuroleptics Schizophrenia Spectrum Disorders

Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications

OBJECTIVE: Despite concerns about the adverse effects of second-generation antipsychotics on weight regulation and glucose and lipid metabolism, little is known about the relationship between these agents and the metabolic syndrome. Because the metabolic syndrome is more strongly associated with cardiovascular morbidity and mortality than its individual components, attention to the full syndrome is important. The authors’ goal was to explore the relationship between second-generation antipsychotics and the metabolic syndrome. METHOD: They assessed the prevalence of metabolic syndrome in a nearly consecutive group of 89 acutely admitted psychiatric inpatients treated with at least one second-generation antipsychotic for different psychiatric disorders. Patients’ waist circumference and blood pressure were measured as well as their fasting blood glucose and lipid levels. RESULTS: Twenty-six (29.2%) of the 89 patients fulfilled criteria for the metabolic syndrome. Presence of the syndrome was associated with older age, higher body mass index, and higher values for each individual criterion of the metabolic syndrome but not with specific diagnoses or antipsychotic treatment regimens. Presence of abdominal obesity was most sensitive (92.0%), while fasting glucose >110 mg/dl was most specific (95.2%) in correctly identifying the presence of metabolic syndrome. Combining abdominal obesity and elevated fasting blood glucose had 100% sensitivity. CONCLUSIONS: The measurement of both abdominal obesity and fasting blood glucose is a simple, cost-effective screening test to detect patients at high risk for future cardiovascular morbidity.

This article has been cited by other articles:

				C. U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J. M. Kane, and A. K. Malhotra Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents JAMA, October 28, 2009; 302(16): 1765 - 1773. [Abstract] [Full Text] [PDF]

				R. Reeves, H. Kaldany, J. Lieberman, and R. Vyas Creation of a Metabolic Monitoring Program for Second-Generation (Atypical) Antipsychotics Journal of Correctional Health Care, October 1, 2009; 15(4): 292 - 301. [Abstract] [PDF]

				G. Goodwin and Consensus Group of the British Association for Psy Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology J Psychopharmacol, June 1, 2009; 23(4): 346 - 388. [Abstract] [PDF]

				R. I. Holt Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 199 - 204. [Abstract] [PDF]

				R. S. McIntyre and J. Z. Konarski Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions Focus, October 1, 2005; 3(4): 511 - 519. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us